Literature DB >> 8375129

The influence of dose and ethnic origins on the pharmacokinetics of nifedipine.

C H Ahsan1, A G Renwick, D G Waller, V F Challenor, C F George, M Amanullah.   

Abstract

The pharmacokinetics of nifedipine capsules was investigated in healthy young Caucasian and South Asian subjects. Both the area under the plasma concentration-time curve (AUC) and terminal half-life of nifedipine were significantly higher in South Asians compared with Caucasian subjects after single oral doses of 10 and 20 mg. The AUC and half-life values of the nitropyridine metabolite were also higher in South Asians than in Caucasian subjects. The serum protein binding of nifedipine was similar in the two groups. The pharmacokinetics were essentially linear in both Caucasian subjects (0 to 30 mg; n = 27) and South Asians (0 to 20 mg; n = 16). There was no indication of a separate subgroup of Caucasian subjects with high AUC values equivalent to the poor metabolizers reported previously. Pharmacodynamic modeling for South Asians gave estimates comparable to those previously reported in Caucasian subjects. Patients of South Asian origin may require lower doses of nifedipine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375129     DOI: 10.1038/clpt.1993.155

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 4.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

5.  Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

Authors:  Sandra M Swain; Young-Hyuck Im; Seock-Ah Im; Valorie Chan; David Miles; Adam Knott; Emma Clark; Graham Ross; José Baselga
Journal:  Oncologist       Date:  2014-05-28

6.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

7.  Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.

Authors:  A Sowunmi; T J Rashid; O O Akinyinka; A G Renwick
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 8.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

9.  Factors affecting the absolute bioavailability of nifedipine.

Authors:  T J Rashid; U Martin; H Clarke; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

Review 10.  Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.

Authors:  P Glue; R P Clement
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.